BSE/TSE
This article was originally published in The Tan Sheet
Executive Summary
HHS meeting for industry input on how department's BSE/TSE Action Plan "can capitalize on the human and physical resources of the pharmaceutical and biotechnology industries" will be held Sept. 24, 9 a.m. at the Hubert Humphrey Building, 200 Independence Ave., SW, Washington, D.C. Plan, which was unveiled Aug. 23, notes FDA will expand policies to prevent potential exposure to TSE through drugs, foods, dietary supplements by using pre-approval reviews and "targeted post-marketing review of specific entities that may either contain at-risk bovine material" or may be exposed to at-risk materials during manufacture. Action plan says FDA will "pursue studies to evaluate the safety and effectiveness of sterilization/decontamination/inactivation procedures" that can become part of GMPs
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
People In Brief
Perrigo promotes in pricing, planning
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: